ClinicalTrials.gg
CompletedNCT00566865Updated Feb 18, 2009

Drug-Drug Interaction Study of Mitiglinide and Gemfibrozil

A Phase 1 interventional study of placebo for gemfibrozil and gemfibrozil in Type 2 Diabetes Mellitus, sponsored by Elixir Pharmaceuticals. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-02-18.

Sponsored by Elixir Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The primary objective of this study is to determine the extent of effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of mitiglinide.

02

Conditions studied

  • Type 2 Diabetes Mellitus
03

In context

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 14 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Elixir Pharmaceuticals is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • non-smoker
  • (BMI) of 19-28 kg/m2
  • no relevant food allergies

Exclusion criteria

Exclusion Criteria:

  • any subject for whom gemfibrozil is
  • any subject with a history of hypoglycemia or who tend to get easily hypoglycemic
  • history of or current abnormality or disease of any organ system
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    2

    mitiglinide + gemfibrozil

    Drug: gemfibrozil

  • Placebo comparator
    1

    mitiglinide + placebo for gemfibrozil

    Drug: placebo for gemfibrozil

Interventions

  • Drugplacebo for gemfibrozil

    mitiglinide + placebo for gemfibrozil 600 mg bid

  • Mitiglinide + 600 mg gemfibrozil bid

06

What researchers measure

Primary outcomes

  1. pharmacokinetics of mitiglinide

    Time frame: 3 days of treatment with gemfibrozil

  2. pharmacodynamics of mitiglinide

    Time frame: 3 days of treatment with gemfibrozil

Secondary outcomes

  1. safety and tolerance of mitiglinide when co-administered with 600 mg gemfibrozil

    Time frame: 3 days of treatment with gemfibrozil

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2007
First posted
Dec 4, 2007
Start
Nov 2007
Primary completionActual
Dec 2007
CompletionActual
Dec 2007
Last update
Feb 18, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00566865
Lead sponsor
Elixir Pharmaceuticals
First posted
Dec 4, 2007
Start date
Nov 2007
Primary completion
Dec 2007
Completion
Dec 2007
Last update
Feb 18, 2009

Study contacts

Erin Nulf, RN, BSN
study director · Quintiles Phase I Services

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gemfibrozil

Start the discussion